Prof Ho Sup Yoon is the President of CHA Advanced Research Institute. He is concurrently Executive Vice President (Research) and Professor of Biochemistry and Structural Biology at the College of Pharmacy at CHA University, Korea. He is also Visiting Professor at the School of Biological Sciences, Nanyang Technological University (NTU) Singapore. Prof Yoon received his BSc from Seoul National University, MSc from Korea Advanced Institute of Science and Technology (KAIST), and Ph.D. (Biochemistry & Molecular Biology) from the University of Chicago. Before joining NTU, he worked as a Sr. Research Scientist at Abbott Laboratories, USA. Prof Yoon has done pioneering research in deciphering the Pleckstrin homology (PH) domain's molecular mechanisms that recognize phosphoinositides. Moreover, the three-dimensional structural portrait of the pro-survival Bcl-2 family proteins facilitated structure-based drug design towards the developing of Venetoclax, a medication to treat patients with chronic lymphocytic lymphoma and acute myeloid leukemia. Prof Yoon's current research program focuses on the anti-cell death proteins' structural plasticity, immunophilins' roles in human diseases, the transcriptional activation mechanism of orphan nuclear receptors, and intrinsically disordered proteins in conformational protein disorders such as Parkinson's Disease. Prof Yoon's service contributions have been impeccable, serving various roles and capacities. Since he joined the School of Biological Sciences, Nanyang Technological University Singapore, in February 2002 as one of the founding faculty members, he served as Head of the Chemical Biology and Biotechnology Division and Structural Biology and Biochemistry Division, Director of the Biosciences Research Centre at the School of Biological Sciences, and appointed Biomedical Research Director in the President's Office, NTU and coordinated NTU's biomedical and translational research portfolios. He also served on various committees for academic affairs and public agencies. Prof Yoon has published more than 160 journal papers and conference proceedings. He also has rendered his service to the research community as a reviewer for multiple peer-reviewed journals. He served on the Singapore Phenome Center Steering Committee, the NTU-Commonwealth Scientific and Industrial Research Organization (CSIRO) Steering Committee, and the Ministry of Health Singapore Committee to develop the Code of Ethical Practice in Human Biomedical Research in Singapore. Prof Yoon received the Abbott Drug Discovery Impact Award 2000 from Abbott Laboratories and the Overseas Korean Scientist of the Year Award from the Ministry of Science and ICT, Republic of Korea, in November 2018. In July 2016, Prof Yoon was elected a Fellow of The Royal Society of Chemistry (FRSC).

As a PhD in reproductive physiology, Professor Ko possesses over 40 years of expertise in the biomedical industry, and thus can manage business plannings and commercialization within the healthcare and bio businesses.

Having excellent research results and clinical experience in infertility research and clinical trials, which are becoming more important in a low fertility and aging society, Professor Ko can produce population policies and medical administration to cope such societal problems. After taking office as the director of the infertility laboratory at Cha Hospital Fertility Center (Research Director), he has founded the Reproductive Medicine Research Headquarters and the CHA Advanced Research Institute. Conducted research and clinical practice in reproductive medicine. Has won eight thesis awards at numerous international conferences. Has led the development of reproductive medicine and infertility treatment technology in Korea by publishing 102 SCI level research papers.

Has experience in attracting foreign patients and implementing overseas medical industry. Ability to establish a proven k-medical global profit model. Prior to the increase in foreign patients in 2010, Professor Ko has established a "life center Chaum" as an optimized business model for attracting foreign patients, which was gained great responses from patients in Russia, Central Asia, Southeast Asia, etc. Has served as the director of planning and coordination at Sungkwang Medical Foundation (Cha Hospital) and head of the planning headquarters and actively led projects for overseas expansions. Has conducted business feasibility analysis and commercialization of 81 centers mergers and acquisitions and MOUs currently held in 7 countries. Established numerous commercialization models using healthcare, such as exporting medical technology and attracting medical tourism to Korea As a PhD in reproductive physiology, Professor Ko possesses over 40 years of expertise in the biomedical industry, and thus can manage business plannings and commercialization within the healthcare and bio businesses.

Hyun Jung Helen Lee MD, MHCM is a board-certified gynecologist and an experienced pharmaceutical professional. Dr. Lee joined CHA Biothech as President (Research & Development). She also has been jointly appointed Vice President (Research & Development) at CHA Advanced Research Institute. She brings to CHA Bio group over 20 years’ experience of R&D of new drugs in the biotech and pharmaceutical industries leading to successful registrations and approvals of new drugs. She also has the experience in development and execution of lifecycle plans of marketed drugs, business development and innovative corporate strategies. Most recently she was the CEO of Samyang Biopharmaceuticals USA. She also held multiple leadership roles in various global pharmaceutical companies including the Global Head, VP of clinical development of solid tumor at Shire, Global Lead of oncology clinical development at Baxter, Global lead of clinical development at Eli Lilly and Product physician of oncology at Pfizer.

Dr. Lee obtained her medical degree from the Medical school of Yonsei University and completed her resident training at the Severance Hospital of Yonsei University in Seoul, Korea and master degree in Health Care management at the school of public health of Harvard University, in Boston, USA.

In 2020, She was featured in the 2020 PharmaVOICE 100, a listing of 100 of the most Inspiring People in Life Sciences Industry in the USA.